These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 31034960)

  • 1. RNAi therapeutic and its innovative biotechnological evolution.
    Weng Y; Xiao H; Zhang J; Liang XJ; Huang Y
    Biotechnol Adv; 2019; 37(5):801-825. PubMed ID: 31034960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical advances of siRNA therapeutics.
    Hu B; Weng Y; Xia XH; Liang XJ; Huang Y
    J Gene Med; 2019 Jul; 21(7):e3097. PubMed ID: 31069898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leading RNA Interference Therapeutics Part 1: Silencing Hereditary Transthyretin Amyloidosis, with a Focus on Patisiran.
    Titze-de-Almeida SS; Brandão PRP; Faber I; Titze-de-Almeida R
    Mol Diagn Ther; 2020 Feb; 24(1):49-59. PubMed ID: 31701435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re-Engineering RNA Molecules into Therapeutic Agents.
    Egli M; Manoharan M
    Acc Chem Res; 2019 Apr; 52(4):1036-1047. PubMed ID: 30912917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patisiran: First Global Approval.
    Hoy SM
    Drugs; 2018 Oct; 78(15):1625-1631. PubMed ID: 30251172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current state and future directions of RNAi-based therapeutics.
    Setten RL; Rossi JJ; Han SP
    Nat Rev Drug Discov; 2019 Jun; 18(6):421-446. PubMed ID: 30846871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis.
    Kristen AV; Ajroud-Driss S; Conceição I; Gorevic P; Kyriakides T; Obici L
    Neurodegener Dis Manag; 2019 Feb; 9(1):5-23. PubMed ID: 30480471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patisiran for the treatment of patients with familial amyloid polyneuropathy.
    Rizk M; Tüzmen S
    Drugs Today (Barc); 2019 May; 55(5):315-327. PubMed ID: 31131842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. siRNA therapeutics: a clinical reality.
    Saw PE; Song EW
    Sci China Life Sci; 2020 Apr; 63(4):485-500. PubMed ID: 31054052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vutrisiran: First Approval.
    Keam SJ
    Drugs; 2022 Sep; 82(13):1419-1425. PubMed ID: 35997942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.
    González-Duarte A; Berk JL; Quan D; Mauermann ML; Schmidt HH; Polydefkis M; Waddington-Cruz M; Ueda M; Conceição IM; Kristen AV; Coelho T; Cauquil CA; Tard C; Merkel M; Aldinc E; Chen J; Sweetser MT; Wang JJ; Adams D
    J Neurol; 2020 Mar; 267(3):703-712. PubMed ID: 31728713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.
    Adams D; Gonzalez-Duarte A; O'Riordan WD; Yang CC; Ueda M; Kristen AV; Tournev I; Schmidt HH; Coelho T; Berk JL; Lin KP; Vita G; Attarian S; Planté-Bordeneuve V; Mezei MM; Campistol JM; Buades J; Brannagan TH; Kim BJ; Oh J; Parman Y; Sekijima Y; Hawkins PN; Solomon SD; Polydefkis M; Dyck PJ; Gandhi PJ; Goyal S; Chen J; Strahs AL; Nochur SV; Sweetser MT; Garg PP; Vaishnaw AK; Gollob JA; Suhr OB
    N Engl J Med; 2018 Jul; 379(1):11-21. PubMed ID: 29972753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I
    Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies, design, and chemistry in siRNA delivery systems.
    Dong Y; Siegwart DJ; Anderson DG
    Adv Drug Deliv Rev; 2019 Apr; 144():133-147. PubMed ID: 31102606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
    Traber GM; Yu AM
    J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Growing Class of Novel RNAi Therapeutics.
    Traber GM; Yu AM
    Mol Pharmacol; 2024 Jun; 106(1):13-20. PubMed ID: 38719476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of siRNA Therapeutics for the Treatment of Liver Diseases.
    Holm A; Løvendorf MB; Kauppinen S
    Methods Mol Biol; 2021; 2282():57-75. PubMed ID: 33928570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.
    Jing X; Arya V; Reynolds KS; Rogers H
    Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNAi for Developing Targeted Therapeutics--CHI's Third Annual Meeting.
    Plane G
    IDrugs; 2010 Jan; 13(1):20-2. PubMed ID: 20024842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic siRNA: state of the art.
    Hu B; Zhong L; Weng Y; Peng L; Huang Y; Zhao Y; Liang XJ
    Signal Transduct Target Ther; 2020 Jun; 5(1):101. PubMed ID: 32561705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.